Tags

Type your tag names separated by a space and hit enter

O-(beta-hydroxyethyl)-rutosides systemic and local treatment in chronic venous disease and microangiopathy: an independent prospective comparative study.
Angiology. 2008 Feb-Mar; 59 Suppl 1:7S-13S.A

Abstract

O-(beta-hydroxyethyl)-rutosides (HR) is used to treat chronic venous disease and signs and symptoms of chronic venous insufficiency (CVI), varicose veins, and deep venous disease. This independent prospective controlled trial (a registry study) evaluates how the efficacy of HR at the local level (perimalleolar region) can be increased by the administration of a topical HR gel. The study is based on evaluation of microcirculatory variables in patients with severe CVI (ambulatory venous pressure, > 56 mm Hg) and venous microangiopathy. Patients are treated using 1 of the following 3 regimens: oral treatment with 1 g sachets of HR (2 g/d total) plus topical HR 2% gel applied 3 times daily at the internal perimalleolar region; oral treatment only (same dosage), or light elastic compression stockings. Laser Doppler skin flux at rest, skin flux at the perimalleolar region, and transcutaneous PO2 and PCO2 are measured at baseline and at the end of the treatment period. A comparable group of healthy individuals without treatment is observed for 8 weeks. In the treatment groups, flux is increased, PO2 is decreased, and PCO2 is increased compared with normal skin. At 4 and 8 weeks, the improvement in skin flux (which is decreased by all measurements), the increase in PO2, and the decrease in PCO2 (indicating microcirculatory improvement) are statistically significantly greater in the combined oral plus topical treatment group (P < .05). No adverse effects, tolerability problems, or compliance issues are noted. These results indicate an important role of HR in the treatment and control of CVI and venous microangiopathy.

Authors+Show Affiliations

Department of Biomedical Sciences, Chieti-Pescara University, and the San Valentino Vascular Screening Project, Italy. Cardres@abol.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Controlled Clinical Trial
Journal Article

Language

eng

PubMed ID

18287162

Citation

Belcaro, Gianni, et al. "O-(beta-hydroxyethyl)-rutosides Systemic and Local Treatment in Chronic Venous Disease and Microangiopathy: an Independent Prospective Comparative Study." Angiology, vol. 59 Suppl 1, 2008, 7S-13S.
Belcaro G, Rosaria Cesarone M, Ledda A, et al. O-(beta-hydroxyethyl)-rutosides systemic and local treatment in chronic venous disease and microangiopathy: an independent prospective comparative study. Angiology. 2008;59 Suppl 1:7S-13S.
Belcaro, G., Rosaria Cesarone, M., Ledda, A., Cacchio, M., Ruffini, I., Ricci, A., Ippolito, E., Di Renzo, A., Dugall, M., Corsi, M., Marino Santarelli, A. R., & Grossi, M. G. (2008). O-(beta-hydroxyethyl)-rutosides systemic and local treatment in chronic venous disease and microangiopathy: an independent prospective comparative study. Angiology, 59 Suppl 1, 7S-13S. https://doi.org/10.1177/0003319707312021
Belcaro G, et al. O-(beta-hydroxyethyl)-rutosides Systemic and Local Treatment in Chronic Venous Disease and Microangiopathy: an Independent Prospective Comparative Study. Angiology. 2008 Feb-Mar;59 Suppl 1:7S-13S. PubMed PMID: 18287162.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - O-(beta-hydroxyethyl)-rutosides systemic and local treatment in chronic venous disease and microangiopathy: an independent prospective comparative study. AU - Belcaro,Gianni, AU - Rosaria Cesarone,Maria, AU - Ledda,Andrea, AU - Cacchio,Marisa, AU - Ruffini,Irma, AU - Ricci,Andrea, AU - Ippolito,Edmondo, AU - Di Renzo,Andrea, AU - Dugall,Mark, AU - Corsi,Marcello, AU - Marino Santarelli,Anna Rita, AU - Grossi,Maria Giovanna, PY - 2008/4/9/pubmed PY - 2008/4/18/medline PY - 2008/4/9/entrez SP - 7S EP - 13S JF - Angiology JO - Angiology VL - 59 Suppl 1 N2 - O-(beta-hydroxyethyl)-rutosides (HR) is used to treat chronic venous disease and signs and symptoms of chronic venous insufficiency (CVI), varicose veins, and deep venous disease. This independent prospective controlled trial (a registry study) evaluates how the efficacy of HR at the local level (perimalleolar region) can be increased by the administration of a topical HR gel. The study is based on evaluation of microcirculatory variables in patients with severe CVI (ambulatory venous pressure, > 56 mm Hg) and venous microangiopathy. Patients are treated using 1 of the following 3 regimens: oral treatment with 1 g sachets of HR (2 g/d total) plus topical HR 2% gel applied 3 times daily at the internal perimalleolar region; oral treatment only (same dosage), or light elastic compression stockings. Laser Doppler skin flux at rest, skin flux at the perimalleolar region, and transcutaneous PO2 and PCO2 are measured at baseline and at the end of the treatment period. A comparable group of healthy individuals without treatment is observed for 8 weeks. In the treatment groups, flux is increased, PO2 is decreased, and PCO2 is increased compared with normal skin. At 4 and 8 weeks, the improvement in skin flux (which is decreased by all measurements), the increase in PO2, and the decrease in PCO2 (indicating microcirculatory improvement) are statistically significantly greater in the combined oral plus topical treatment group (P < .05). No adverse effects, tolerability problems, or compliance issues are noted. These results indicate an important role of HR in the treatment and control of CVI and venous microangiopathy. SN - 0003-3197 UR - https://www.unboundmedicine.com/medline/citation/18287162/O__beta_hydroxyethyl__rutosides_systemic_and_local_treatment_in_chronic_venous_disease_and_microangiopathy:_an_independent_prospective_comparative_study_ L2 - https://journals.sagepub.com/doi/10.1177/0003319707312021?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -